The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

A case of employment termination of a physician assistant (PA) who had a decade’s old contract with her employer. Was the ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

Significant changes from previous guideline include recommendation that only FSH >25 IU required for POI diagnosis.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.

Dr. Renee Wynn is a doctorally educated, board-certified Women's Health Nurse Practitioner who focuses on perinatal and reproductive health justice. She is an Assistant Professor ...

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

Supplementation with cholecalciferol 1,000 IU/day during pregnancy is associated with greater offspring bone mineral density during childhood.